Dr. Tinashe Chandauka is a life science company builder with a MD/PhD, venture capital and business development background. He is an EiR at the Texas Medical Center’s Accelerator for Cancer Therapeutics. Prior to this role, he was Director, Early Pipeline Development at Tarsus Pharmaceuticals, an Irvine based ophthalmology company. He began his company creation career as an Associate at Oxford Science Enterprises (OSE), an Oxford based venture capital fund backed by Sequoia, Google Ventures and Goldman Sachs and other limited partners. He was part of early-stage company builds across cell, gene, vaccine and immuno-oncology therapies. He was a founding member of OSE’s portfolio management team. In addition, he served on the Board of Circadian Therapeutics through its Series A fundraise. Outside of work, Tinashe is a Director and Trustee of AMREF Health Africa UK. He received his PhD from the University of Oxford where he was Rhodes Scholar. He obtained his medical degree from the University of Cape Town with distinction. In Texas, he is excited and motivated to identify, build and launch several pioneering biotechnology companies that address cancer and rare diseases.